111 related articles for article (PubMed ID: 16204288)
1. An oral load of the early glycation compound lactuloselysine fails to accumulate in the serum of uraemic patients.
Schwenger V; Morath C; Schönfelder K; Klein W; Weigel K; Deppisch R; Henle T; Ritz E; Zeier M
Nephrol Dial Transplant; 2006 Feb; 21(2):383-8. PubMed ID: 16204288
[TBL] [Abstract][Full Text] [Related]
2. Advanced glycation end products in renal failure.
Thornalley PJ
J Ren Nutr; 2006 Jul; 16(3):178-84. PubMed ID: 16825015
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation endproducts (AGEs) as uremic toxins.
Schwenger V; Zeier M; Henle T; Ritz E
Nahrung; 2001 Jun; 45(3):172-6. PubMed ID: 11455783
[TBL] [Abstract][Full Text] [Related]
4. Advanced glycation end product free adducts are cleared by dialysis.
Agalou S; Ahmed N; Thornalley PJ; Dawnay A
Ann N Y Acad Sci; 2005 Jun; 1043():734-9. PubMed ID: 16037300
[TBL] [Abstract][Full Text] [Related]
5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
6. Effects of haemodialysis and continuous ambulatory peritoneal dialysis on the plasma clearance of an albumin-bound furan dicarboxylic acid.
Costigan MG; Yaqoob M; Lindup WE
Nephrol Dial Transplant; 1995; 10(5):648-52. PubMed ID: 7566577
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of glyoxal and methylglyoxal levels in uremic patients under peritoneal dialysis.
Lapolla A; Flamini R; Lupo A; Aricò NC; Rugiu C; Reitano R; Tubaro M; Ragazzi E; Seraglia R; Traldi P
Ann N Y Acad Sci; 2005 Jun; 1043():217-24. PubMed ID: 16037242
[TBL] [Abstract][Full Text] [Related]
8. Activation of L-arginine transport in undialysed chronic renal failure and continuous ambulatory peritoneal dialysis patients.
Brunini TM; Roberts NB; Yaqoob MM; Ellory JC; Mann GE; Mendes Ribeiro AC
Clin Exp Pharmacol Physiol; 2006; 33(1-2):114-8. PubMed ID: 16445709
[TBL] [Abstract][Full Text] [Related]
9. Profound mishandling of protein glycation degradation products in uremia and dialysis.
Agalou S; Ahmed N; Babaei-Jadidi R; Dawnay A; Thornalley PJ
J Am Soc Nephrol; 2005 May; 16(5):1471-85. PubMed ID: 15800128
[TBL] [Abstract][Full Text] [Related]
10. Tryptophan and its metabolites in patients on continuous ambulatory peritoneal dialysis and following renal transplantation.
Qureshi AR; Lindholm B; Garcia E; Groth CG; Bergström J
Nephrol Dial Transplant; 1994; 9(7):791-6. PubMed ID: 7526276
[TBL] [Abstract][Full Text] [Related]
11. Studies on absorption and elimination of dietary maillard reaction products.
Förster A; Kühne Y; Henle T
Ann N Y Acad Sci; 2005 Jun; 1043():474-81. PubMed ID: 16037269
[TBL] [Abstract][Full Text] [Related]
12. Oxalic Acid as a uremic toxin.
Mydlík M; Derzsiová K
J Ren Nutr; 2008 Jan; 18(1):33-9. PubMed ID: 18089441
[TBL] [Abstract][Full Text] [Related]
13. The association of advanced glycation end-products with glutathione status.
Sahin E; Göçmen AY; Koçak H; Tuncer M; Gümüslü S
Ann Clin Biochem; 2008 Jul; 45(Pt 4):369-74. PubMed ID: 18583621
[TBL] [Abstract][Full Text] [Related]
14. Advanced glycation end products in renal failure: an overview.
Noordzij MJ; Lefrandt JD; Smit AJ
J Ren Care; 2008 Dec; 34(4):207-12. PubMed ID: 19090900
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation end products stimulate tumor necrosis factor-alpha and interleukin-1 beta secretion by peritoneal macrophages in patients on continuous ambulatory peritoneal dialysis.
Rashid G; Korzets Z; Bernheim J
Isr Med Assoc J; 2006 Jan; 8(1):36-9. PubMed ID: 16450750
[TBL] [Abstract][Full Text] [Related]
16. The role of tryptophan, 5-hydroxy indole-3-acetic acid and their protein binding in uremic patients.
Qureshi GA; Baig SM
Biochem Mol Biol Int; 1993 Mar; 29(3):411-9. PubMed ID: 7683549
[TBL] [Abstract][Full Text] [Related]
17. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
[TBL] [Abstract][Full Text] [Related]
18. First evidence for accumulation of protein-bound and protein-free pyrraline in human uremic plasma by mass spectrometry.
Odani H; Shinzato T; Matsumoto Y; Takai I; Nakai S; Miwa M; Iwayama N; Amano I; Maeda K
Biochem Biophys Res Commun; 1996 Jul; 224(1):237-41. PubMed ID: 8694819
[TBL] [Abstract][Full Text] [Related]
19. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.
Gugliucci A; Mehlhaff K; Kinugasa E; Ogata H; Hermo R; Schulze J; Kimura S
Clin Chim Acta; 2007 Feb; 377(1-2):213-20. PubMed ID: 17118352
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of polyneuropathy severity in chronic renal failure patients on continuous ambulatory peritoneal dialysis or on maintenance hemodialysis].
Janda K; Stompór T; Gryz E; Szczudlik A; Drozdz M; Kraśniak A; Sułowicz W
Przegl Lek; 2007; 64(6):423-30. PubMed ID: 18159852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
